B-PO02-139 MAPPING AND ABLATION OF INAPPROPRIATE SINUS TACHYCARDIA: BEST OF BOTH?

Radiofrequency catheter ablation of inappropriate sinus tachycardia guided by activation mapping

Three-dimensional nonfluoroscopic mapping and ablation of inappropriate sinus tachycardia: Procedural strategies and long-term outcome

Partial Cardiac Denervation and Sinus Node Modification for Inappropriate Sinus Tachycardia

BackgroundSystemic lupus erythematosus (SLE) is known to cause inappropriate sinus tachycardia (IST). However, there is limited evidence available with regard to the treatment of IST in this setting. In this article, we report a case of drug refractory IST in a patient with SLE treated with radiofrequency catheter ablation (RFCA) using a non-contact mapping system.Case summaryA 33-year-old woman had been diagnosed with SLE in 2001. She presented with complaints of persistent palpitations for 1 month and persistent sinus tachycardia. She underwent RFCA using a non-contact mapping system for drug refractory IST. The voltage and activation maps did not show obvious differences in the earliest activation site at heart rates (HRs) 90–150 b.p.m. In contrast, the areas of breakout sites were clearly distinguished between those from the normal P-wave zones at HR <140 b.p.m. and those from higher rate sites at HR >140 b.p.m. Radiofrequency catheter ablation was performed in those areas as the target for ablation. Thereafter, the symptoms steadily disappeared and the maximum HR—using 24-h Holter monitoring—decreased from 156 to 120 b.p.m.DiscussionRadiofrequency catheter ablation using a non-contact mapping system was applied to the treatment of drug refractory IST in a patient with SLE. Of note, IST in such patients may be left untreated. This approach may be considered as a first-line therapy option for drug refractory IST in patients with SLE.

Ablation of inappropriate sinus tachycardia: Is it time to review choices?

Inappropriate sinus tachycardia is an ill-defined clinical syndrome with diverse clinical manifestations. Clinical symptoms can range from intermittent palpitations to multisystem complaints. Although there is a general consensus that when the heartbeat exceeds 100 beats per minute at rest or with minimal physiologic challenge, it is considered "inappropriate," this quantitative differentiation is quite arbitrary, while validation of the reproducibility of the heart rate/activity correlation can be challenging. Once the clinical diagnosis of inappropriate sinus tachycardia is expected, other supraventricular tachyarrhythmias and medical conditions causing sinus tachycardia should be excluded. The underlying mechanism of inappropriate sinus tachycardia is not well understood. "Intracardiac" mechanisms such as enhanced intrinsic automaticity, enhanced sympathetic tone, increased sympathetic receptor sensitivity, and blunted parasympathetic tone have been proposed. Evidences for "extracardiac" mechanisms such as length-dependent autonomic neuropathy, excessive venous pooling, beta-receptor hypersensitivity, alpha-receptor hyposensitivity, altered sympathovagal balance, and brainstem dysregulation have also been reported. Currently, our ability to differentiate primary (intracardiac) from secondary (extracardiac) mechanisms of inappropriate sinus tachycardia is limited. It has been reported that ablative therapy of sinus node is effective in treating patients with symptomatic inappropriate sinus tachycardia. Acute success of sinus node modification/ablation can be accomplished in 70%-100% of the various study populations. Although long-term successful outcome may be accomplished in a few patients, symptoms of palpitations and autonomic characteristics frequently persist. Identification and differentiation of patients who are suitable for ablative therapy versus medical therapy should be one of the central clinical research issues in this patient population. This brief review first considers the clinical and electrophysiologic diagnosis of inappropriate tachycardia and then summarizes the mechanisms of inappropriate sinus tachycardia and related syndromes such as postural orthostatic tachycardia syndrome. Techniques of mapping and ablation of sinus node are discussed briefly. A critical review of the acute and long-term clinical outcomes following sinus node ablation and modification is updated. In conclusion, the precise role of sinus node modification in patients with inappropriate sinus tachycardia remains to be determined. Sinus node modification could be considered in patients with inappropriate sinus tachycardia with persistently increased heart rate in the absence of any autonomic abnormalities. Autonomic laboratory testing should be performed to exclude any evidence of autonomic dysregulation. Clinical research on the pathophysiology of inappropriate sinus tachycardia should be pursued vigorously.

Background: Medical treatment for inappropriate sinus tachycardia (IST) remains suboptimal. Radiofrequency Sinus node Modification (RFSM) has been used for managing drug-refractory symptomatic IST. Although, acute success is reasonable, it is faced with high complications and recurrence rates. A novel Sinus Node sparing surgical thoracoscopic hybrid ablation (SUSRUTA) has been recently proposed. Objective: To report outcomes of SUSRUTA for IST patients from a prospective multicenter registry. Methods: This is a multicenter, prospective registry of patients who received SUSRUTA which is SN sparing hybrid ablation using surgical thoracoscopic video-assisted epicardial ablation comprised of a RF bipolar clamp which was used for sparing the SN region (identified by endocardial 3D mapping) and isolation of superior and inferior vena cava with creation of a lateral line across the crista terminalis during IST with isoproterenol challenge. Gaps in the epicardial lesion set are filled in by endocardial RFA. Patients were treated with post op Colchicine and were enrolled in cardiac rehabilitation program. Results: Of the 139 patients, mean age was 26±4 yrs, 91% women and mean duration of IST was 40±21.5 months. 90% were on ivabradine, 86% on beta-blocker, 77% on calcium channel blocker and 77% were on class IC antiarrhythmic agent. Heart rate post-procedure was significantly lower when compared with pre-procedure (110±10 vs. 64±11 bpm, p&lt;0.0001). After a blanking period of 3 months, normal sinus rhythm was restored in 100% of patients in the hybrid group. Postop pericarditis was the most common complication in 80%(severe-4%), severe bradycardia (HR &lt;35 bpm) in 5%, pneumothorax 3.5% and pleural effusion requiring drainage in 2.1% of cases. One patient required a permanent pacemaker. Hospital length of stay was 4.5±0.8 days. At 1041±541 days follow up 94.5% (131/139) were free of symptoms after a single procedure and the 8 patients required a redo-RF catheter ablation.95% patients are off all preprocedural rate controlling medications Conclusion: SUSRUTA appears to be efficacious and safe for the treatment of symptomatic drug resistant IST.

PO-01-081 EPICARDIAL PHRENIC NERVE DEFLECTION DURING SINUS NODE MODIFICATION

The present study evaluated the clinical benefits of a new therapeutic method of radiofrequency catheter ablation (RFCA) using an EnSite system for inappropriate sinus tachycardia (IST). Six patients with debilitating IST underwent RFCA using EnSite. Using the beta-adrenergic blocker and agonist, the heart rate was controlled between 70 to 150 bpm before and after the RFCA. The areas of the breakout sites (BOSs) were clearly distinguished between those from the normal P-wave zones during rates of less than 100 bpm and those from more upper rate sites during rates of more than 100 bpm using the EnSite system, in accordance with the appearance of tall P-waves (tall P-wave zone) in the IST patients. This was selected as the target for ablation. After the RFCA, the BOSs observed during heart rates of more than 100 bpm moved completely from the tall P-wave zone to the normal P-wave zone in the IST patients. The total number of heart beats and average heart beat on the 24-h Holter monitoring decreased statistically from that before the RFCA to that after, and no adverse heart rate responses was observed after the RFCA. Before the RFCA, the brain natriuretic peptide was elevated, New York Heart Association functional class was worse, and there was an impaired exercise tolerance observed with exercise electrocardiogram testing. The RFCA for the IST significantly improved those parameters. This new therapeutic method for IST using EnSite is effective and produces clinical benefits.

Catheter ablation of inappropriate sinus tachycardia has proven difficult. Despite the use of intracardiac echocardiography to help direct radiofrequency (RF) application to the anatomic target of the superolateral crista terminalis (CT), multiple RF lesions often are required. Furthermore, the characteristic echo-anatomic changes with RF application associated with a reduction in heart rate have not been defined. A characteristic echo signature, if present, may facilitate the ablation process. The purpose of this retrospective study was to define the echocardiographic characteristic changes associated with effective RF ablation for inappropriate sinus tachycardia. Detailed intracardiac echocardiographic imaging characterization of the superolateral CT was performed before and at the time of successful heart rate reduction. Using on-line videotape intracardiac echocardiography (9 MHz, 9 French), changes in wall thickness and echodensity at the CT lesion site were assessed at baseline, after each RF lesion, and with the lesion that produced heart rate reduction in 17 patients (age 32 +/- 9 years; 15 women) with inappropriate sinus tachycardia. In all patients, RF ablation was anatomically based and targeted only the superolateral CT. RF lesions were created using 20 to 50 W for up to 2 minutes using an 8-mm tip electrode. Successful heart rate reduction (> or = 20 beats/min) was achieved in 15 of 17 patients and required 41 +/- 31 RF applications (range 5 to 110, median 40). Effective RF (reduced heart rate) was observed starting with the 34th +/- 24th lesion (range 3rd to 86th, median 25th). After effective RF, CT wall thickness was increased (11.4 +/- 3.1 mm vs 7.7 +/- 2.4 mm at baseline) and wall swelling expanded to adjacent superior vena cava, but the degree of thickening was not specific for effective RF associated with heart rate reduction. Importantly, we noted echodensity changes reaching directly to the epicardium with the development of a linear low echodensity or echo-free space at the time of effective RF resulting in heart rate reduction. In two patients without effective heart rate reduction, echodensity changes never reached the epicardium. No complications (superior vena cava-right atrial junction orifice narrowing >50% or pericardial effusion) of RF were identified. An echocardiographically guided anatomic approach to RF ablation of inappropriate sinus tachycardia is safe and effective. A characteristic echocardiographic signature suggesting transmural/epicardium damage appears to be present at the time of successful heart rate reduction and may serve as an appropriate guide for directing additional RF when using this anatomic echocardiographically based approach.

Inappropriate sinus tachycardia (IST) has been defined as a resting heart rate of >100 beats per minute and an average 24-hour heart rate >90 bpm with distressing symptoms resulting from the persistent tachycardia. IST is prevalent in 1% of the middle-aged population, mostly females. Rarely can elderly patients also present with IST. Possible mechanisms of IST include intrinsic sinus node abnormality, beta-adrenergic receptor stimulating autoantibody, beta-adrenergic receptor supersensitivity, muscarinic receptor autoantibody, or hyposensitivity, impaired baroreflex control, depressed efferent parasympathetic/vagal function, nociceptive stimulation, central autonomic overactivity, aberrant neurohumoral modulation, etc. Symptoms associated with IST are palpitations, chest pain, fatigue, shortness of breath, presyncope, and syncope. Despite these distressing symptoms, IST has not been associated with tachycardia-associated cardiomyopathy or increased major cardiovascular events. Various treatment options for patients with IST are ivabradine, beta-adrenergic blockers, calcium channel blockers, psychiatric evaluation, and exercise training. Although, endocardial radiofrequency ablation targeting the sinus node has been used as a treatment modality for otherwise treatment-refractory IST, the results have been dismal. The other modalities used for refractory IST treatment are endocardial modification of the sinus node using radiofrequency energy, combined endo and epicardial ablation of the sinus node, thoracoscopic epicardial ablation of the sinus node, sinus node sparing thoracoscopic and endocardial hybrid ablation. The goal of this review is to provide the readership with the pathophysiological basis of IST and its management options.

Introduction: Inappropriate Sinus Tachycardia (IST) is a cardiac dysautonomia with limited treatment options. This case highlights the effectiveness of a novel sinus node-sparing hybrid surgical ablation (SNSHA) for IST. Objective: To describe a novel hybrid surgical approach for management of IST. Case Description: A 43 y/o female presented with history of palpitations/tachycardia for 5 years. A comprehensive evaluation directed towards the diagnosis of IST with resting heart rates (HR) above 100 bpm and HR changes greater than 30% with minimal exertion. A trial of ivabradine &amp; beta blockers along with lifestyle modifications offered limited relief. Patient was offered the novel SNSHA after a shared decision-making process. Methods: The SNSHA is a minimally invasive procedure performed by a CT surgeon in conjunction with an electrophysiologist involving thoracoscopic epicardial ablation of the sympathetic connections from the SVC to the IVC. The thoracoscopic approach allows for safeguarding of the phrenic nerve and sinus node followed by endocardial ablation along the lateral wall. Results: Intraprocedural pre and post ablation electroanatomic map (EAM) and electrogram (EGM) demonstrated an immediate drop in HR as shown in the Figure 1(a-d). An ILR was implanted during the procedure. On 45-day post-op visit, the patient experienced significant symptom relief and improvement in her HR as well as HR variability on ILR as shown in Figure 1(e). Conclusion: SNSHA offers a reasonable treatment option for patients with drug resistant IST. This procedure provided symptom alleviation and improvement in HR without increasing the risk of complications in comparison to sinus node modification ablation, which has previously been shown to be associated with higher incidence of pacemaker implantation.

The management of atrial fibrillation, even in the modern era, remains complex and challenging. Preventing atrial fibrillation occurrence by identifying and favorably improving modifiable risk factors thus assumes great importance. It is well known that hypertension and resultant structural heart disease contributes significantly to the incidence of atrial fibrillation.1,2 The Losartan Intervention For End point reduction in hypertension (LIFE) study thus far has shown us that angiotensin-receptor blockade and reduction in left ventricular hypertrophy, irrespective of blood pressure–lowering, reduces the incidence of new-onset atrial fibrillation.1,3 Article see p 337 In recent years, accumulating evidence has linked high resting sinus heart rates (HR) directly and indirectly to adverse cardiovascular outcomes.4,5 Epidemiological studies show resting HR to be an independent predictor of cardiovascular and all-cause mortality in general population as well as in hypertensive patients.6 The cardiovascular benefits offered by β-blockade in coronary artery disease and heart failure have, in part, been attributed to β-blocker–mediated HR reduction.7,8 Other studies have linked high baseline HR to the development of hypertension, to the progression of coronary artery disease, and to the triggering of myocardial infarction, ventricular dysfunction, and ventricular arrhythmias.6,9–11 In this issue of Circulation: Arrhythmia and Electrophysiology , Okin and colleagues12 examines the relationship of HR changes over time on risk of atrial fibrillation in hypertensive patients as part of the LIFE study. In this post hoc analysis of the prospective LIFE study, 8828 hypertensive patients with left ventricular hypertrophy by ECG but without a history of atrial fibrillation were followed for a mean of 4.7±1.1 years. New onset atrial fibrillation was determined by 12-lead ECG performed on an intermittent, infrequent basis (at baseline, 6 months, and yearly thereafter). Hypertension was treated with losartan or atenolol. Using a variety of analyses, higher in-treatment HR on serial …

Inappropriate sinus tachycardia (IST) is a rare type of arrhythmia that is currently difficult to treat successfully. The effects of laser catheter applications aimed at the sinus nodal area were tested experimentally and the technique was used for the treatment of IST. Continuous-wave, mapping-guided 1,064 nm neodymium-doped yttrium aluminum garnet laser applications at 15 W (9.5 W/mm2) per 15 seconds (142.5 J/mm2) and an irrigation flow of 30 mL/min were aimed at the sinus nodal area in five dogs (three applications each) and one human patient (two applications) by use of an 8-French open-irrigated electrode-laser mapping and ablation (ELMA) catheter provided with three miniature pin electrodes (0.5 mm × 4.0 mm) with interelectrode distances of 2.0 mm arranged symmetrically and radially around the endhole of the catheter tip. Laser application was aimed at the largest and earliest atrial potentials recorded in the focused local electrograms 30 ms to 45 ms prior to the onset of the P-wave in the surface lead electrocardiogram. Lesions were evaluated morphometrically. Holter monitoring in the patient was performed prior to and after treatment. During laser application in the dogs, sinus nodal potential amplitudes dwindled gradually from a mean of 42 mm ± 24 mm to 5.0 mm ± 3.0 mm and sinus cycle lengths lengthened from 452 ms ± 35 ms to 634 ms ± 35 ms (p < 0.0001 for both). In the patient, electrical potential amplitudes in the local electrograms dwindled from 41.0 mm to 5.0 mm and, in the Holter monitor, heart rate decreased from 109 bpm ± 29 bpm to 79 bpm ± 26 bpm (p < 0.0001). IST ablation was painless and without complications. During a follow-up of 4.9 years, the patient was asymptomatic and her heart rate and chronotropic competence remained normal. In conclusion, ablation of IST was achieved by substrate mapping-guided laser application while using the open-irrigated EMLA catheter RytmoLas (LasCor GmbH – Laser Medical Devices, Taufkirchen, Germany). However, this is a proof-of-concept study and further research, preferably in the form of multicenter study trials, is needed for confirmation of the results.

Late Outcomes of Surgical Ablation for Inappropriate Sinus Tachycardia